Plasma Protease C1-inhibitor Treatment Market Research Scope Industry Chain Analysis & Opportunities 2018 to 2026 | CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc.

The research report Plasma Protease C1-inhibitor Treatment Market Analysis 2020 provides an estimate of the market size from 2020 to 2026 in terms of value and volume. It also includes a full assessment of key market segments and Plasma Protease C1-inhibitor Treatment Market shares with the latest trends and technologies used in the energy industry, as well as an instructive overview of the vendor landscape and geographic expansion of the market. The research study examines the Plasma Protease C1-inhibitor Treatment Market based on a number of criteria such as Product Type, Application and geographic extent. The market shares of these segments are formulated in such a way that they offer readers of the Plasma Protease C1-inhibitor Treatment Market an opportunistic Roadmap.

Hereditary angioedema (HAE) is an autosomal disorder characterized by low levels of functional C1 esterase inhibitor protein. Purified concentrate of C1 esterase inhibitors are used in HAE affected patients for the prophylactic and acute attack treatment of HAE. Several plasma protease C1-inhibitors such as Cinryze, Firazyr, Kalbitor, and Berinet have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

Global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% during the forecast period (2020-2027).

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4262

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

Global Plasma Protease C1-inhibitor Treatment Market – Drivers

The increasing focus of biopharmaceutical companies on development of effective plasma protease C1-inhibitor treatment drugs/therapy treating various health conditions such as HAE, diabetic macular edema (DME), and others, is expected to drive growth of the plasma protease C1-inhibitor treatment market. Several kallikrein inhibitor therapies are currently in preclinical and clinical development stages. For instance, in September 2019, Oxurion released positive topline data from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME). Moreover, in December 2019, KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME).

Furthermore, adoption of inorganic growth strategies such as partnerships and collaborations, in order to develop innovative protease C1-inhibitor treatment is significantly contributing to the growth of global plasma protease C1-inhibitor treatment market. For instance, in October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 (investigational plasma kallikrein inhibitors). The company’s investigational intravitreal (IVT) injection candidate is currently in development for potential treatment of diabetic macular edema (DME).

Market Dynamics

Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.

Buy Now This Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4262

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Plasma Protease C1-inhibitor Treatment industry.

Market Segmentation: This section provides a detailed analysis of type and application segments of the Plasma Protease C1-inhibitor Treatment industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Plasma Protease C1-inhibitor Treatment industry.

Market Dynamics: The report offers deep insights into the dynamics of the Plasma Protease C1-inhibitor Treatment industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Plasma Protease C1-inhibitor Treatment industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Plasma Protease C1-inhibitor Treatment industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Plasma Protease C1-inhibitor Treatment industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Plasma Protease C1-inhibitor Treatment industry.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.